Pharmacogenomics/updated for precision medicine in dermatology

References

• Su S-C, Chung W-H, Hung S-I. Digging up the human genome: current progress in deciphering adverse drug reactions. BioMed Res Int. 2014;2014:1.
   Google Scholar
• Cotto KC, Wagner AH, Feng Y-Y, et al. DGIdb 3.0: a redesign and expansion of the drug–gene interaction database. Nucleic Acids Res. 2018;46:D1068–D1073.
   PubMedGoogle Scholar
• Hicks JK, Dunnenberger HM, Gumpper KF, et al. Integrating pharmacogenomics into electronic health records with clinical decision support. Am J Health Syst Pharm. 2016;73:1967–1976.
   PubMed Web of Science ®Google Scholar
• Bell GC, Crews KR, Wilkinson MR, et al. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc. 2014;21:e93–e99.
   PubMed Web of Science ®Google Scholar
• Overby CL, Devine EB, Abernethy N, et al. Making Pharmacogenomic-based prescribing alerts more effective: a scenario-based pilot study with physicians. J Biomed Inform. 2015;55:249–259.
   PubMed Web of Science ®Google Scholar
• NISHIMURA AA, SHIRTS BH, DORSCHNER MO, et al. Development of clinical decision support alerts for pharmacogenomic incidental findings from exome sequencing. Genet Med. 2015;17:939–942.
   PubMed Web of Science ®Google Scholar
• Health Quality Ontario BrenerStaceyHolubowichCorinne, Brener S, Holubowich C. Pharmacogenomic testing for psychotropic medication selection: a systematic review of the assurex genesight psychotropic test. Ontario Health Technology Assessment Series. 2017;17:1–39.
   Google Scholar
• Drozda K, Müller DJ, Bishop JR. Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options. Pharmacotherapy. 2014;34:166–184.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research (CDER). Science & Research (Drugs) – Table of Pharmacogenomic Biomarkers in Drug Labeling. 2018, June [cited 2018, Jun 23]. Available from: https://www.fda.gov/drugs/scienceresearch/ucm572698.htm
   Google Scholar
• Roos WP, Quiros S, Krumm A, et al. B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells. Oncotarget. 2014;5:12607–12620.
   PubMedGoogle Scholar
• Trivedi MK, Shinkai K, Murase JE. A review of hormone-based therapies to treat adult acne vulgaris in women. Int J Women’s Dermatol. 2017;3:44–52.
   PubMedGoogle Scholar
• Jourabchi N, Rhee SM, Lazarus GS. Premenstrual flares of pyoderma gangrenosum controlled with use of a combined oral contraceptive and antiandrogen (ethinyl estradiol/drospirenone). Br J Dermatol. 2016;174:1096–1097.
   PubMed Web of Science ®Google Scholar
• Greenfield NP, Maibach H. Pharmacogenomic biomarkers in dermatologic drugs. J Dermatolog Treat. 2013;24:408–410.
   PubMed Web of Science ®Google Scholar
• Lorenzo CR, Koo J. Pimozide in dermatologic practice: a comprehensive review. Am J Clin Dermatol. 2004;5:339–349.
   PubMed Web of Science ®Google Scholar
• Hagen R, Ghareeb E, Jalali O, et al. Infantile hemangiomas: what have we learned from propranolol? Curr Opin Pediatr. 2018;30:499–504.
   PubMed Web of Science ®Google Scholar
• De Giorgi V, Grazzini M, Benemei S, et al. Propranolol for off-label treatment of patients with melanoma: results from a cohort study. JAMA Oncol. 2018;4:e172908.
   PubMed Web of Science ®Google Scholar
• Gupta MA, Gupta AK. Antidepressant drugs in dermatology. Skin Therapy Lett. 2001;6:3–5.
   PubMedGoogle Scholar
• Shah VV, Aldahan AS, Mlacker S, et al. 5-Fluorouracil in the treatment of keloids and hypertrophic scars: a comprehensive review of the literature. Dermatol Ther. 2016;6:169–183.
   Web of Science ®Google Scholar
• Callen JP. Safe use of systemic agents in dermatology – Chicagoderm. 2006, Apr [cited 2018 Jun]. Available from: https://www.chicagoderm.org/assets/docs/MonthlyMtg/Resources/callen - malkinson lecture.pdf
   Google Scholar
• Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014;306:103–124.
   PubMed Web of Science ®Google Scholar
• Gleghorn K, Wilson J, Wilkerson M. Rituximab: uses in Dermatology. Skin Therapy Lett. 2016;21:5–7.
   PubMedGoogle Scholar
• Schram ME, Borgonjen RJ, Bik CMJM, et al. Off-label Use of Azathioprine in dermatology: a systematic review. Arch Dermatol. 2011;147:474–488.
   PubMedGoogle Scholar
• Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–417.
   PubMed Web of Science ®Google Scholar
• Haga SB, Kantor A. Horizon scan of clinical laboratories offering pharmacogenetic testing. Health Aff. 2018;37:717–723.
   Web of Science ®Google Scholar
• Schweitzer J, Maibach H. Pharmacogenomics in dermatology: taking patient treatment to the next level. J Dermatolog Treat. 2015;26:94–96.
   PubMed Web of Science ®Google Scholar
• Rizzo AE, Maibach HI. Personalizing dermatology: the future of genomic expression profiling to individualize dermatologic therapy. J Dermatolog Treat. 2012;23:161–167.
   PubMed Web of Science ®Google Scholar
• Johnson MR, Hageboutros A, Wang K, et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999;5:2006–2011.
   PubMed Web of Science ®Google Scholar
• Kishi P, Price CJ. Life-threatening reaction with topical 5-fluorouracil. Drug Saf Case Rep. 2018;5:4.
   PubMedGoogle Scholar
• Altar CA, Carhart JM, Allen JD, et al. Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics J. 2015;15:443–451.
   PubMed Web of Science ®Google Scholar
• Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017;17:395–402.
   PubMed Web of Science ®Google Scholar
• Benet LZ. Predicting Pharmacokinetics/Pharmacodynamics in the individual patient: separating reality from hype. J Clin Pharmacol. 2018. doi: 10.1002/jcph.1105.
   PubMedGoogle Scholar